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Summary
 
Two novel human 
 
b
 
-chemokines, Ck
 
b
 
-8 or myeloid progenitor inhibitory factor 1 (MPIF-1), and
Ck
 
b
 
-6 or MPIF-2, were discovered as part of a large scale cDNA sequencing effort. The
MPIF-1 and MPIF-2 cDNAs were isolated from aortic endothelium and activated monocyte
libraries, respectively. Both of the cDNAs were cloned into a baculovirus vector and expressed
in insect cells. The mature recombinant MPIF-1 protein consists of 99 amino acids and is most
homologous to macrophage inflammatory protein (MIP)-1
 
a
 
, showing 51% identity. It displays
chemotactic activity on resting T lymphocytes and monocytes, a minimal but significant activ-
ity on neutrophils, and is negative on activated T lymphocytes. MPIF-1 is also a potent sup-
pressor of bone marrow low proliferative potential colony-forming cells, a committed progen-
itor that gives rise to granulocyte and monocyte lineages. The mature recombinant MPIF-2 has
93 amino acid residues and shows 39 and 42% identity with monocyte chemoattractant protein
(MCP)-3 and MIP-1
 
a
 
, respectively. It displays chemotactic activity on resting T lymphocytes,
a minimal activity on neutrophils, and is negative on monocytes and activated T lymphocytes.
 
On eosinophils, MPIF-2 produces a transient rise of cytosolic Ca
 
2
 
1
 
 and uses the receptor for
eotaxin and MCP-4. In hematopoietic assays, MPIF-2 strongly suppressed the colony forma-
tion by the high proliferative potential colony-forming cell (HPP-CFC), which represents a
multipotential hematopoietic progenitor.
 
C
 
hemokines are cytokines that stimulate proinflamma-
tory activity by eliciting the chemotactic migration of
leukocytes and their adhesion to endothelial cells (1–8). All
the chemokines have an 8–10-kD molecular mass, exhibit
20–75% homology at the amino acid level, and are charac-
terized by four conserved cysteine residues that form two
disulfide bonds. Based on the arrangement of the first two
cysteines, they have been classified as 
 
a
 
- or 
 
b
 
-chemokines.
The 
 
a
 
-chemokines show the first two cysteines separated
by one amino acid (C-X-C motif) while the 
 
b
 
-chemokines
are characterized by two contiguous cysteines (C-C motif)
(9, 10).
Structural analysis shows that 
 
b
 
-chemokines cluster in
two major groups. The first group includes monocyte chemo-
attractant protein (MCP)-1, MCP-2, MCP-3, MCP-4, and
eotaxin, the second group includes macrophage inflamma-
tory protein (MIP)-1
 
a
 
, MIP-1
 
b
 
, and RANTES. All the
MCP chemokines are NH
 
2
 
 terminally blocked, attract acti-
vated T lymphocytes, and are without activity on neutro-
phils. All of them except eotaxin are chemotactic for
monocytes and all of them except MCP-1 activate eosino-
phils. With the exception of MCP-1, MCP chemokines
are not active on freshly purified resting T lymphocytes. (9,
11–16).
The 
 
b
 
-chemokines of the second group, MIP-1
 
a
 
, MIP-
1
 
b
 
, and RANTES are chemotactic for activated T lympho-
cytes and monocytes. However, MIP-1
 
a
 
 is also active on
eosinophils and, moderately active on neutrophils, whereas
RANTES attracts eosinophils and resting and activated T
lymphocytes (9, 11, 12). Finally, MIP-1
 
a
 
 and MIP-1
 
b
 
 exi-
bit activity on hematopoiesis. MIP-1
 
a
 
 inhibits the primi-
tive bone marrow progenitors as defined by spleen colony
assay (CFU-S), and MIP-1
 
b
 
 prevents the inhibitory activ-
ity of MIP-1
 
a
 
 (13, 14). Both MIP-1
 
a
 
 and MIP-1
 
b
 
 inhibit
megakaryocyte development (15).
This paper describes two novel 
 
b
 
-chemokines, Ck
 
b
 
-8
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or myeloid progenitor inhibitory factor (MPIF)
 
1
 
 1 that ex-
hibits homology to MIP-1
 
a
 
 and Ck
 
b
 
-6 or MPIF-2 that ex-
hibits homology to both MIP-1
 
a
 
 and MCP-3. MPIF-1 and
MPIF-2 inhibit two distinct classes of myeloid progenitors
in vitro.
 
Materials and Methods
 
Materials, Reagents, and Chemicals.
 
HBSS, IMDM, RPMI
1640, and MEM tissue culture media, 
 
l
 
-glutamine, penstrep, and
poly (A) RNA purification kits were purchased from GIBCO
BRL (Gaithersburg, MD). Heat-inactivated fetal bovine serum
(FBS), histopaque 1077 and 1119, DMSO, platelet-activating fac-
tor (PAF), and PMA were from Sigma Chemical Co. (St. Louis,
MO). MyeloCult
 
Ô
 
 H5100 and MethoCult
 
Ô
 
 H4535 media
were purchased from Stem Cell Technologies Inc. (Vancouver,
Canada). Bacto-agar was from Difco Labs. (Detroit, MI). EX-
CELL 400 medium was from J.R. Scientific (Woodland, CA).
Tissue culture grade plasticware was from Costar Corp. (Cam-
bridge, MA). QBEND/10 CD34 cell isolation kit, RS and CS col-
umns, and VarioMac were purchased from Miltenyi Biotech Inc.
(Sunnyvale, CA). The cDNA ZAP Express synthesis kits were
from Stratagene Corp. (La Jolla, CA). Poly (A) RNA from vari-
ous tissues was purchased from Clontech (Palo Alto, CA). Nylon
membranes for Northern blot analysis were from Zetabind (Cuno,
Inc., Meriden, CT). Restriction enzymes and protease inhibitors
were from Boehringer Mannheim (Indianapolis, IN). POROS
CM20 and HS50 columns were from PerSeptive Biosystems
(Framingham, MA). Sephacryl S-200 was from Pharmacia Bio-
Process Technology ASB (Uppsala, Sweden). ProBlott
 
Ô
 
 mem-
branes and Blot Cartridges
 
TM
 
 were from Perkin-Elmer Corp./
Applied Biosystems, (Foster City, CA). PA-1 column was from
Dionex Corp. (Sunnyvale, CA). Limulus amebocyte lysate assay
was from Associates of Cape Cod, Inc. (Woods Hole, MA). The
intracellular fluorescence probes were from Molecular Probes
Inc. (Eugene, OR).
 
mAbs and Cytokines.
 
The mAbs were purchased from Becton
Dickinson (San Jose, CA). The mAb HIT3a anti–human CD3
was from PharMingen (San Diego, CA). Human and mouse re-
combinant cytokines were purchased from R&D Sys., Inc. (Min-
neapolis, MN). MCP-4 was produced as reported (16).
 
Cell Lines and Viruses.
 
The cell lines Sf9 (CRL-1711), K562
(CCL-243), HL60 (CRL-1964), THP-1 (TIB-202), Jurkat (TIB-
152), Molt-3 (CRL-1552), RS4-11 (CRL-1873), CCRF-CEM
(CCL-119), KG1 (CCL-246), and KG1a (CCL-246.1) were from
American Type Culture Collection (Rockville, MD). Most of the
cell lines were cultured in RPMI 1640 supplemented with 10%
FBS, 2 mM 
 
l
 
-glutamine, and penstrep. KG1 and KG1a cells were
grown in IMDM with 10% FBS. For the chemical induction
studies, 
 
z
 
2 
 
3
 
 10
 
6
 
 K562 or HL-60 cells were distributed in T-75
flasks with 20 ml of fresh media with or without 1% DMSO or 10
 
m
 
M PMA, and processed for total RNA at various time points. Sf9
cells were grown at 27
 
8
 
C in EX-CELL 400 medium with 1%
FBS. The 
 
Autographa californica
 
 virus was from PharMingen.
 
cDNA Libraries, RNA Isolation, and Northern Blot Analysis.
 
Poly (A) RNA was purified from a variety of tissues or cell lines
using purification kits according to the manufacturer’s recom-
mendations. Total RNA was isolated using the guanidine isothio-
cynate–CsCl
 
2
 
 method (17). All the cDNA libraries were then
constructed by using the ZAP-cDNA kit according to the manu-
facturer’s instructions. Poly (A) RNA (1 
 
m
 
g) from tissues or total
RNA from cell lines (10 
 
m
 
g) were fractionated on a 1% agarose-
formaldehyde gel, transferred to nylon membranes, and hybrid-
ized under high stringency conditions with 
 
32
 
P-cDNA probes as
previously described (18).
 
Automated Gene Sequencing.
 
Bacterial colonies containing plas-
mids  with inserts were selected, lysed, and the cDNA insert was
amplified by PCR. Expressed sequence tag (EST) clones were dis-
covered as reported (19, 20). The EST clones used in this study
were the result of a collaboration between The Institute for Ge-
nomic Research (Gaithersburg, MD) and Human Genome Sci-
ences, Inc. (Rockville, MD). For sequence analysis and assembly,
Sequencher Software (version 2.1.1; Gene Codes Corp., Ann Ar-
bor, MI) was used.
 
Expression and Purification of Recombinant Proteins.
 
The coding se-
quences of MPIF-1 and MPIF-2 were amplified by PCR during
which unique restriction sites (BglII and Asp 718) were intro-
duced and then cloned into the baculovirus transfer vector A2.
This vector contains the 
 
b
 
-galactosidase gene of 
 
Escherichia coli
 
 to
facilitate the identification of recombinant viruses that form blue
plaques. The Sf9 cells were infected at a multiplicity of infection
of two and the supernatant of the infected culture was collected af-
ter 72 h. The recombinant MPIF-1 and MPIF-2 were purified in
the presence of protease inhibitors (20 
 
m
 
g/ml pefabloc SC, 1 
 
m
 
g/
ml leupeptin, 1
 
m
 
g/ml E-64, and 1 mM EDTA) on a POROS HS
50 cation exchange column. The column was eluted with 500 mM
NaCl in 40 mM Na acetate buffer at pH 5.5; the chemokine pos-
itive fractions were pooled and diluted with a 40 mM Na acetate
buffer, pH 5.5, to adjust NaCl concentration to 100 mM. This
mixture was applied to a POROS CM20 cation exchange col-
umn and eluted with a linear salt gradient (0.1–1 M NaCl). The
positive fractions were pooled and applied to a Sephacryl S-200
column. The resulting preparations were 
 
.
 
95% pure as deter-
mined by SDS-PAGE. Endotoxin was monitored by the limulus
amebocyte lysate assay.
The NH
 
2
 
-terminal amino acid sequence of purified MPIF-1
and MPIF-2 was analyzed by an ABI-494 sequencer (Perkin-Elmer).
The glycosylation of each chemokine was determined by a Di-
onex carbohydrate analyzer (21).
 
Human Blood Cells.
 
Peripheral blood mononuclear neutro-
phils, eosinophils, T lymphocytes, monocytes, and PBMC were pur-
ified from single donor leukopacks (American Red Cross, Rock-
ville, MD) as previously described (22–24).
Resting T lymphocytes were enriched by negative selection by
passing PBMC on T cell columns (R&D Sys.) that retained
monocytes and B lymphocytes. Resting CD4
 
1
 
 and CD8
 
1
 
 T lym-
phocytes were 90% pure. Enriched T lymphocytes (CD4
 
1
 
 and
CD8
 
1
 
) were activated by 16 h incubation in RPMI medium in
the presence of 10 U/ml IL-2 in 100-mm dishes coated with
HIT3a mAb anti–CD3 (1 
 
m
 
g/ml). Elutriated monocytes were
70–80% pure as assessed by CD14 positivity. Eosinophils were
 
.
 
95% pure as assessed on stained cytospun preparations. CD34
 
1
 
cells were isolated from 45 ml of cord blood collected with 5 mM
EDTA and 20 U/ml heparin. After 10 min centrifugation at 200 
 
g
 
the buffycoat was resuspended in PBS supplemented with 5 mM
EDTA (PBS/EDTA) and centrifuged on histopaque 1077. The
cells were collected, washed, resuspended in cold PBS/EDTA
 
1
 
Abbreviations used in this paper:
 
 CFC, colony-forming cells; Epo, erythro-
poietin; EST, expressed sequence tag; FBS, fetal bovine serum; GM,
granulocyte and monocyte; h, human; HPP, high proliferative potential;
LPP, low proliferative potential; m, mouse; MCP, monocyte chemoat-
tractant protein; MIP, macrophage inflammatory protein; MPIF, myeloid
progenitor inhibitory factors; PAF, platelet-activating factor; SCF, stem
cell factor. 
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with 0.5% BSA, and subjected to the QBEND/10 kit and mag-
netic cell sorting according to the manufacturer’s instructions. This
procedure yielded a 95% CD34
 
1
 
 population of cells.
 
Mouse Bone Marrow Cells.
 
Bone marrow cells were isolated
from 6–8-wk-old C57Bl/6 female mice (Jackson Labs., Bar Har-
bor, ME) according to Metcalf (25). In brief, cells were obtained
from the femur and tibia by flushing with IMDM 5% FBS and cen-
trifuged at 750 
 
g
 
 for 30 min over a cushion of histopaque 1119.
Cells sedimenting at the interface were washed with IMDM me-
dium, plated in 10-cm dishes, and incubated for 1 h at 37
 
8
 
C to
remove plastic adherent cells. The nonadherent cell population
was used in clonogenic assays.
 
Chemotaxis.
 
Cells were washed in HBSS with 0.1% BSA
(HBSS/BSA) and resuspended in the same medium at 2 
 
3
 
 10
 
6
 
/ml
with 1 
 
m
 
M calcein-AM. After 30 min at 37
 
8
 
C, the cells were
washed in HBSS/BSA, resuspended in the same medium at 8 
 
3
 
10
 
6
 
/ml, and 25 
 
m
 
l of this suspension was dispensed into each up-
per chamber of a 96-well chemotaxis plate filter (Neuro Probe,
Cabin John, MD). Different concentrations of the chemotactic
agents were distributed in the bottom chamber of each well. Cells
were allowed to migrate for 45–90 min through the polycarbon-
ate filter between upper and bottom chambers (5–8 
 
m
 
m pores;
polyvinylpyrrolidone-free), and the number of migrated cells
(both attached to the bottom surface of the filter as well as in the
bottom chamber) were quantitated using a fluorescence plate
reader (Cytofluor PerSeptive Biosystems). The ratio between the
number of cells migrated in the presence of chemokines and the
number of cells migrated in the presence of buffer control is de-
fined as the chemotactic index.
 
Ca
 
2
 
1
 
 Mobilization.
 
Monocytes were loaded for 30 min at
37
 
8
 
C with 4 
 
m
 
M Indo-1/acetoxymethylester per 5 
 
3
 
 10
 
6
 
 cells/ml
in prewarmed buffer (1 mM CaCl
 
2
 
, 2 mM MgSO4, 5 mM glu-
cose, 10 mM Hepes buffer, pH 7.4). Cells were then washed, re-
suspended in the same buffer at 5 3 105 cells/ml, and stimulated
with the indicated chemokines at 378C. Eosinophils were loaded
with 2.5 mM fura-2/5 3 106 cells/ml in prewarmed buffer (1 mM
CaCl2, 1 mM MgCl2, 125 mM NaCl, 5 mM KCl, 0.5 mM glu-
cose, 20 mM Hepes, pH 7.4, 0.025% BSA). Cells were washed in
loading buffer and resuspended at 106 cells/ml. The fluorescence
signal induced by the changes in the intracellular Ca21 was mea-
sured on a fluorescence spectrophotometer (F-2000; Hitachi In-
struments Inc., San Jose, CA) by monitoring Indo-1 excitation at
330 nm, emission at 405 and 485 nm, and fura-2 excitation at
340 and 380 nm, emission at 510 nm.
Clonogenic Assays on Mouse Bone Marrow Cells. High prolifer-
ative potential colony-forming cells (HPP-CFC) and low prolif-
erative potential CFC (LPP-CFC) colony-formation assays were
performed in a two-layered agar culture system as described by
Bradley and Hodgson (26). In brief, the bottom layer was pre-
pared in 3.5-cm diam dishes with 1 ml of MEM supplemented
with 20% FBS, 0.5% Difco agar, 7.5 ng/ml mouse (m)IL-3, 150
ng/ml mouse stem cell factor (mSCF), 7.5 ng/ml human monocyte
(hM)-CSF, and 15 ng/ml mIL-1a. Chemokines were incorpo-
rated into the bottom agar where indicated. This layer was then
overlayed with 0.5 ml of murine bone marrow cell suspension to
have 1,500 cells/dish in MEM with 20% FBS and 0.3% agar. The
dishes were then incubated for 14 d in a tissue culture incubator
(378C, 88% N2, 5% CO2, and 7% O2) and colonies were scored
under an inverted microscope. In these conditions HPP-CFC
and LPP-CFC gives rise to colonies that are .5 mm and ,1 mm
diam, respectively (27, 28). In some experiments, impact of
MPIF-1 and MPIF-2 on the growth of burst-forming unit–eryth-
roid (BFU-E), CFU-E, and CFU–granulocyte and monocyte
(GM) was also determined. In brief, 5 3 104 bone marrow cells
were suspended in 1 ml of MethoCultÔ semisolid medium and
plated in 3.5-cm dishes. For CFU-E assay, the medium was sup-
plemented with 3 U/ml h erythropoietin (Epo) and the dishes
were incubated for 2 d. The hemoglobinized colonies (4–16 cells/
colony) were identified by acid benzidine stain and scored under
an inverted microscope. For BFU-E and CFU-GM assay, the
medium was supplemented with 5 ng/ml mIL-3, 10 ng/ml mGM-
CSF, and 3 U/ml hEpo. The dishes were incubated for 11 d and
the colonies were scored under an inverted microscope.
Clonogenic Assay of hCD341 Progenitors. CD341 cord blood
cells (5 3 104 cells/ml) were cultured in myelocultTM medium
supplemented with 10 ng/ml hIL-3 and 50 ng/ml hSCF for 4 d
at 378C in a tissue culture incubator (5% CO2, 7% O2, and 88%
N2). The resulting populations of progenitors were suspended
(103 cells/ml) in MethocultTM semisolid medium supplemented
with a cocktail of cytokines (10 ng/ml hIL-3, 10 ng/ml hGM-CSF,
50 ng/ml hSCF, 3U/ml hEpo, and 10 ng/ml h thrombopoietin),
and plated in the presence or absence of chemokines. Colonies
were allowed to grow by incubating the dishes at 378C in a hu-
midified incubator (5% CO2, 7% O2, and 88% N2) for 14 d, and
colonies were scored under an inverted microscope.
Figure 1. The nucleotide sequences of human MPIF-1 (A) and MPIF-2
(B) cDNAs are shown along with the deduced amino acid sequence using
a single letter amino acid code. The underlined NH2-terminal amino ac-
ids represent the leader sequences that were experimentally determined of
proteins expressed in baculovirus expression system. These sequence data are
available from EMBL/GenBank/DDBJ under accession number U85767
for MPIF-1 and U85768 for MPIF-2. (See note added in proof.)1166 MPIF-1 and MPIF-2 Inhibition of Distinct Myeloid Progenitors
Results
Characterization of the MPIF-1 and MPIF-2 cDNA Clones.
The ESTs representing MPIF-1 and MPIF-2 cDNAs were
identified in the Human Genome Sciences, Inc. data base
on the basis of the C-C motif and the homology with
known b-chemokines. The MPIF-1 cDNA clone was iso-
lated from a human aortic endothelial library. Sequencing
of both strands of the insert revealed a full coding region for
a 120–amino acid protein, of which the 21 NH2-terminal
amino acids represent the signal peptide (Fig. 1 A). In com-
parison with the known human b-chemokines, MPIF-1
shows six cysteine residues and is most closely related to
hMIP-1a, exhibiting 51% identity and 67% similarity over
a stretch of 99 amino acids (Fig. 2). The amino acid se-
quence of MPIF-1 revealed no N-linked glycosylation
sites. The MPIF-2 cDNA clone was isolated from an acti-
vated monocyte library and encodes for a 119–amino acid
protein, of which the 26 NH2-terminal amino acids represent
the signal peptide (Fig. 1 B). MPIF-2 is a b-chemokine with
four cysteine residues that exhibits 39% identity and 59%
similarity to MCP-3, and 42% identity and 65% similarity
to MIP-1a over a stretch of 93 amino acids. The overall
comparison of MPIF-1 with MPIF-2 revealed 30% identity
and 50% similarity to one another (not shown).
Tissue Distribution of MPIF-1 and MPIF-2. MPIF-1 ESTs
were most frequently found in the liver, lung, and bone
marrow cDNA libraries, but MPIF-2 ESTs were restricted
to the activated monocyte and T lymphocyte cDNA librar-
ies. To confirm this observation, Northern blot analysis was
performed. As shown in Fig. 3 A, MPIF-1 cDNA hybrid-
ized to a 0.8-kb mRNA species that is most abundant in
the adult lung and liver (Fig. 3 A, lanes 7 and 8), and is
present at moderate levels in fetal liver (Fig. 3 A, lane 4), adult
bone marrow and placenta (Fig. 3 A, lanes 11 and 13).
Analysis of various cell lines showed that MPIF-1 mRNA
is readily detectable in myelomonocytic cell lines (Fig. 3
B). Similar analysis with MPIF-2 cDNA turned out nega-
tive. The MPIF-2 mRNA was only detectable by reverse
transcriptase-PCR in monocytes activated with GM-CSF
for 96 h and in T lymphocytes activated by mAb anti–CD3
(HIT3a) in the presence of IL-2 (not shown).
MPIF-1 and MPIF-2 Expression, Purification, and Analy-
sis. Recombinant MPIF-1 and MPIF-2 proteins were ex-
pressed in Sf9 insect cells infected with a recombinant bac-
ulovirus. SDS-PAGE analysis of a purified MPIF-1 prepa-
ration revealed a single Coomassie blue–stained band with
a molecular mass of 11–12 kD (Fig. 4 A). Edman degrada-
tion analysis showed that the MPIF-1 protein was pro-
Figure 2. Comparison of the amino acid sequences of human MPIF-1
(A) and MPIF-2 (B) with the human b-chemokines MIP-1a, MCP-2,
MCP-3, and MCP-4. The regions of amino acid sequence homology were
determined according to MegAlign Program (version 1.05; DNASTAR
Inc., Madison, WI).
Figure 3. (A) Northern blot analysis of MPIF-1 mRNA steady-state
levels in various human tissues (A) and cell lines (B). (A) Upper panel was
probed with MPIF-1 cDNA, whereas lower panel with actin cDNA.1167 Patel et al.
cessed to yield a protein with RVTKDAE as the NH2-ter-
minus and an expected molecular mass of z11.2 kD, thus
confirming that the observed sequence is identical to that pre-
dicted from the cDNA sequence (Fig. 4 C). Consistent with
the lack of N-glycosylation sites no mannose or N-acetyl-
glucosamine were detected in the MPIF-1 protein.
Amino acid sequence analysis indicated that the NH2
terminus of the MPIF-2 protein is not blocked and begins
with VVIPSP (Fig. 4 C). This predicts the calculated mo-
lecular mass of the mature MPIF-2 protein to be 10.5 kD,
which is in agreement with the SDS-PAGE analysis of Coo-
massie blue–stained protein (Fig. 4 B). MPIF-2 contains up
to 0.9 moles of N-acetylglucosamine or mannose per mole
of the protein. No galactose or N-acetylgalactosamine were
detected, suggesting the absence of O-linked oligosaccha-
rides.
Chemotactic Activity of MPIF-1 and MPIF-2. The chemo-
tactic  properties of MPIF-1 and MPIF-2 were studied on
purified resting and anti-CD3–activated T lymphocytes,
neutrophils, and monocytes. The activity on T lympho-
cytes and monocytes was tested in comparison with MCP-1,
which is a potent attractant for these cells. The activity on
neutrophils was tested, and compared with IL-8. Several
experiments were performed using cells obtained from dif-
ferent donors, and representative experiments are summa-
rized in Fig. 5.
On resting T lymphocytes, MPIF-1 reached its maxi-
mum activity at 10 ng/ml, and was more potent and three
times more effective than MCP-1. In contrast, MPIF-2 and
MCP-1 showed comparable potency and efficacy (Fig. 5 C).
Both MPIF-1 and MPIF-2 were negative on anti-CD3–
activated T lymphocytes (Fig. 5 D). MPIF-1 induced mi-
gration of monocytes at concentrations ranging from 100
ng/ml to 1 mg/ml, but this activity was not observed with
all the monocyte preparations tested. MPIF-2 was negative
on monocytes (Fig. 5 B). Both MPIF-1 and MPIF-2 in-
duced some migration of neutrophils. Although minimal,
this activity was consistently evident at 50 ng/ml, whereas
IL-8 was already four times more potent at 10 ng/ml (Fig.
5 A).
Cytosolic Calcium Changes and Desensitization Experiments.
The capacity of MPIF-1 and MPIF-2 to induce a rapid and
transient rise of cytosolic Ca21 concentration [Ca21]i was as-
sessed on monocytes, and eosinophils. MPIF-1 was active on
monocytes, and MPIF-2 produced changes of [Ca21]i on
eosinophils. On monocytes, a significant rise of the [Ca21]i
was observed using 10 ng/ml MIP-1a, and the maximum
value was recorded at 100 ng/ml MIP-1a. In similar con-
ditions, 1 mg/ml MPIF-1 induced only 50% of the change
of [Ca21]i that was observed with 100 ng/ml MIP-1a. In
the desensitization experiments, the [Ca21]i changes after
repeated stimulation were monitored in monocytes to assess
receptor usage by MPIF-1. The stimulation of monocytes
Figure 4. Analysis of MPIF-1 (A) and MPIF-2 (B) proteins. SDS-
PAGE was performed on 5 mg of purified protein under reducing condi-
tions. The gel was stained with Coomassie blue. Lane 1 of each panel
shows the molecular weight standards. C shows the NH2-terminal se-
quences of MPIF-1 and MPIF-2 proteins as determined by Edman degra-
dation.
Figure 5. Chemotactic activity of MPIF-1 and MPIF-2 on peripheral
blood leukocytes: neutrophils (A), monocytes (B), resting T lymphocytes
(C), and activated T lymphocytes (D). The data for MPIF-1 (open circles),
MPIF-2 (closed circles), IL-8 (closed squares), and MCP-1 (open squares) are
presented as chemotactic index (ratio between the number of cells mi-
grated in the presence of chemokines and the number of cells migrated in
the presence of buffer control). One of three to five experiments per-
formed is shown.1168 MPIF-1 and MPIF-2 Inhibition of Distinct Myeloid Progenitors
with 100 ng/ml MIP-1a abolished responsiveness to 1 mg/
ml MPIF-1, but not to 100 ng/ml MCP-4 (Fig. 6 B).
When monocytes were first exposed to 1 mg/ml MPIF-1
and then to 100 ng/ml MIP-1a followed by 100 ng/ml
MCP-4, MPIF-1 was able to abolish MIP-1a response
without affecting the ability of the same cells to respond to
MCP-4 (Fig. 6 A).
On eosinophils, the magnitude of the [Ca21]i rise in-
creased with the concentration of chemokines tested. A
maximum response was recorded using 500 ng/ml eotaxin
or 1 mg/ml MPIF-2 (data not shown). At the maximal
concentration of 1 mg/ml, the response to MPIF-2 was
z85% of the eotaxin response, while MCP-1 at 1 mg/ml
was negative. In desensitization experiments, the stimula-
tion of eosinophils with 1 mg/ml eotaxin or MCP-4 abol-
ished responsiveness to 1 mg/ml MPIF-2, but not to 1026
M PAF (Fig. 7, A and D). When eosinophils were first ex-
posed to 1 mg/ml MPIF-2 and then to 1 mg/ml eotaxin or
MCP-4, MPIF-2 was found to be able to abolish eotaxin
or MCP-4 response without affecting the ability of the
same cells to respond to PAF (Fig. 7, B and C).
Inhibition of Mouse Myeloid Progenitors. The effects MPIF-1
and MPIF-2 on hematopoietic cells was studied on mouse
low density bone marrow cells plated in methylcellulose-
or agar-containing growth medium supplemented with ap-
propriate combinations of cytokines. No colonies were de-
tected either in the absence of cytokines or in the presence
of either MPIF-1 or MPIF-2 alone. A concentration of 50
Figure 6. Cross-desensitization of human blood monocytes. Indo-
1–loaded cells were stimulated sequentially with 1 mg/ml MPIF-1 and
other b-chemokines (100 ng/ml), and [Ca21]i-dependent fluorescence
changes were recorded. (A) Stimulation with MPIF-1, MIP-1a, and
MCP-4; (B) Stimulation with MIP-1a, MPIF-1, and MCP-4.
Figure 7. Cross-desensitization of human blood eosinophils. Fura-2–loaded
cells were stimulated sequentially with 1 mg/ml MPIF-2 and other
b-chemokines or 1026 M PAF, and [Ca21]i-dependent fluorescence changes
were recorded. (A) Stimulation with eotaxin, MPIF-2, and PAF; (B)
Stimulation with MPIF-2, eotaxin, and PAF; (C) stimulation with MPIF-2,
MCP-4, and PAF; (D) Stimulation with MCP-4, MPIF-2, and MCP-4.1169 Patel et al.
ng/ml MPIF-1 reduced the frequency of CFU-GM and
LPP-CFC colonies to 30% of that found in the control cul-
tures (Table 1). This inhibitory effect of MPIF-1 appeared
to be specific, as MPIF-1 had no effect on colony forma-
tion by CFU-E, BFU-E, and HPP-CFC (Table 1). In con-
trast, 50 ng/ml MPIF-2 produced 80% reduction in the
numbers of HPP-CFC colonies compared to those found
in the control cultures without effects on colony formation
by CFU-E, BFU-E, CFU-GM, and LPP-CFC (Table 1). In
the same conditions, both MCP-4 (50 ng/ml) and MIP-1a
(100 ng/ml) had no effect on colony formation (Table 1
and Fig. 8). The inhibitory effect of MPIF-1 and MPIF-2
was dose dependent (Fig. 9). MPIF-2 reduced HPP-CFC
colonies to 50% of the control at 10 ng/ml (Fig. 9 A),
while MPIF-1 reduced LPP-CFC colonies to 50% of the
control at 20 ng/ml (Fig. 9 B). This experiment confirmed
the specificity of MPIF-1 and MPIF-2 inhibitory effect on
LPP-CFC and HPP-CFC, respectively.
Effect on Human Hematopoietic Progenitors. To determine
the impact of MPIF-1 and MPIF-2 on human hematopoie-
tic cells, CD341 cells were isolated from cord blood and cul-
tured for 4 d in the presence of IL-3 and SCF to generate
hematopoietic progenitors. A limiting dilution of this cell
Table 1. Effect of MPIF-1 and MPIF-2 on the Murine 
Hematopoietic Progenitor Cell Colony Formation In Vitro in Response 
to Known Cytokines
Additions CFU-E
Progenitor colonies
LPP-CFC BFU-E CFU-GM HPP-CFC
CC 94 6 10 13 6 2.5 29 6 3.0 35 6 4.0 114 6 12
1MPIF-1 89 6 11 12 6 2.0 11 6 2.0 29 6 2.0 27 6 6.0
1MPIF-2 91 6 4.0 12 6 3.0 29 6 2.0 8 6 2.0 109 6 14
1MCP-4 91 6 11 12 6 3.0 31 6 4.0 34 6 2.0 116 6 17
CC, appropriate cocktail of cytokines were used as described in Mate-
rials and Methods. Chemokines were added at 50 ng/ml final concen-
tration. Data shown are pooled from two separate experiments and are
expressed as mean 6 SD.
Figure 8. Effect of MPIF-1 and MPIF-2 on the colony formation by
murine HPP-CFC and LPP-CFC in vitro. A population of 1,500 low
density mouse bone marrow cells in semisolid medium with 5 ng/ml
mIL-3, 100 ng/ml mSCF, 10 ng/ml mIL-1a, and 5 ng/ml hM-CSF were
distributed in each plate and cultured with or without 100 ng/ml of the
indicated chemokine for 14 d. The results from two experiments that
were performed in duplicates are presented. The number of colonies gen-
erated in the presence of chemokines is expressed as percentage of those
produced in the absence of any added chemokines 6 SD.
Figure 9. Effect of various concentrations of MPIF-1 (open circles) and
MPIF-2 (closed circles) on the growth and differentiation of HPP-CFC (A)
and LPP-CFC (B). The low density population of mouse bone marrow
cells was plated (1,500 cells/dish) in agar-containing medium with or
without the indicated concentrations of chemokines, but in the presence
of a cytokine cocktail as described in the legend to Fig. 8. The dose-response
curve includes data from three independent experiments that are ex-
pressed as mean 6 SEM.1170 MPIF-1 and MPIF-2 Inhibition of Distinct Myeloid Progenitors
population was then cultured in semisolid medium with
multiple cytokines with or without test chemokines. Data
from two representative experiment are shown in Table 2.
Colony formation by CFU-GM and CFU-Mix in the
presence of either 50 ng/ml MPIF-1 or 50 ng/ml MPIF-2
was reduced by 30–40% compared to those found in the
control cultures (Table 2). Neither 50 ng/ml of MIP-1a
nor MCP-4 affected CFU-GM and CFU-Mix (Table 2).
Discussion
In a large-scale DNA sequencing effort, two novel hu-
man b-chemokines were discovered and named Ckb-8 or
MPIF-1 and Ckb-6 or MPIF-2 for their activity on human
and mouse myeloid progenitors. The cDNA encoding
MPIF-1 has been cloned from a human aortic endothelial
library, and the message for this chemokine is mainly ex-
pressed by macrophages and is detectable in lung, liver,
bone marrow, placenta, and fetal liver. MPIF-1 is not NH2
terminally blocked, and shares 51% identity and 67% simi-
larity with MIP-1a. The chemotactic activity of MPIF-1 is
very potent on resting T lymphocytes, significant on
monocytes, and weak but consistent on neutrophils. Fi-
nally, MPIF-1 has a notable in vitro inhibitory effect on
LPP-CFC, the committed progenitors that give rise to
granulocyte and monocyte lineages and reduces CFU-GM,
but has no significant effects on HPP-CFC multipotent he-
matopoietic progenitors. The experiments performed with
human cord blood CD341-derived cells show that MPIF-1
inhibits both CFU-Mix and CFU-GM, and confirm that
our novel b-chemokine acts on similar targets of both mu-
rine and human origins. MPIF-1 does not show inhibitory
activity on BFU-E or megakaryocyte precursors. Although
the desensitization experiments suggest that MPIF-1 and
MIP-1a may share the same receptor on monocytes, they
are functionally unrelated. MPIF-1 and MIP-1a are active
on different functional stages of T lymphocytes and he-
matopoietic progenitors where they may use distinct recep-
tors. Finally, in comparison with MIP-1a, MPIF-1 is a
more potent inhibitor of hematopoietic progenitors. In our
study, MPIF-1 at 10–50 ng/ml produces 50–80% inhibi-
tion of mLPP-CFC and 50% inhibition of hCFU-GM and
hCFU-Mix (CFU-GEMM), whereas MIP-1a at 100 ng/
ml is ineffective. These data are in agreement with previ-
ously published results showing inhibitory effect of MIP-
1a for BFU-E, CFU-GM, CFU-GEMM, and CFU-Megs
at concentrations ranging from 100 to 500 ng/ml (15, 29,
30). Other studies show that a single addition of MIP-1a
up to 1 mg/ml to the liquid or semisolid system has no ef-
fect on GM-CFU, BFU-E, and multilineage precurors.
Only the daily addition of 100 ng/ml MIP-1a for 6 d pro-
duces inhibition (31, 32).
The recently cloned MRP-2 is a mouse b-chemokine
that shares some characteristics with MIP-1a and shows in-
teresting similarities to MPIF-1. It suppresses in vitro col-
ony formation by mouse and human BFU-E, CFU-GM,
and CFU-GEMM progenitors (33). MPIF-1 and MRP-2
are 42% identical at the amino acid level and show six cys-
teine residues that are conserved with respect to their loca-
tion within both proteins. Due to the fact that the MRP-2
and MPIF-1 cDNAs exhibit only 67% identity and MPIF-1
does not inhibit BFU-E, it is unclear if MPIF-1 represents
the human counterpart of MRP-2. The structural and func-
tional properties we described for MPIF-1 suggest that this
novel b-chemokine may be grouped with MIP-1a, MIP-1b,
RANTES, and mMRP-2.
The novel b-chemokine MPIF-2 is weakly expressed by
activated T lymphocytes and GM-CSF–treated macro-
phages, does not have the NH2 terminus blocked, and ex-
hibits 40% identity and 59% similarity to MCP-3, and 42%
identity and 65% similarity to MIP-1a. MPIF-2 attracts
resting T lymphocytes, activates eosinophils, has minimal acti-
vity on neutrophils, and is negative on monocytes and acti-
vated T lymphocytes. On eosinophils, MPIF-2, eotaxin,
Table 2. Effect of MPIF-1 and MPIF-2 on Human Hematopoietic Progenitor Colony Formation In Vitro
Experiment Additions BFU-E CFU-G CFU-M CFU-GM CFU-Meg CFU-Mix
Colonies/103 cells
1 CC 13 6 2 15 6 2 14 6 3 16 6 3 11 6 3 11 6 2
1 MPIF-1 19 6 2 18 6 5 12 6 28  6  2 12 6 25  6  1
1 MPIF-2 16 6 4 12 6 2 13 6 19  6  3 14 6 33  6  1
1 MIP-1a 17 6 3 19 6 5 14 6 2 14 6 4 12 6 3 12 6 2
2 CC 14 6 3 13 6 3 13 6 1 12 6 3 13 6 1 11 6 2
1 MPIF-1 14 6 2 11 6 1 12 6 25  6  1 12 6 24  6  1
1 MPIF-2 13 6 2 12 6 1 13 6 18  6  2 12 6 36  6  2
1 MIP-1a 12 6 2 12 6 3 13 6 2 13 6 2 14 6 2 12 6 1
1 MCP-4 12 6 1 14 6 2 12 6 1 12 6 2 11 6 1 12 6 2
CC, a cocktail of cytokines was added as described in Materials and Methods. Chemokines were added at 50 ng/ml final concentration. Data from
two representative experiments performed in triplicates are shown and are expressed as mean 6 SD.1171 Patel et al.
and MCP-4 induce comparable transient rise of [Ca21]i. Fi-
nally, MPIF-2 has a notable in vitro inhibitory effect on
mHPP-CFC multipotent hematopoietic precursors with-
out affecting the LPP-CFC–committed progenitors that
give rise to granulocyte and monocyte lineages. Although
the desensitization experiments suggest that MPIF-2, eo-
taxin, and MCP-4 may share the same receptor on eosino-
phils, MPIF-2 may use a different receptor on multipotent
hematopoietic precursors. In fact, MCP-4 does not affect
HPP-CFC multipotent hematopoietic precursors. The struc-
tural and functional properties we described for MPIF-2
show that this novel b-chemokine shares characteristics with
both the MCP and MIP chemokines.
Presently, it is difficult to assess the physiological rele-
vance of the novel b-chemokines we described in this pa-
per. During early stages of inflammation, wound healing,
and delayed-type hypersensitivity reactions, locally activated
macrophages, granulocytes, lymphocytes, and endothelial cells
release  b-chemokines (i.e., MCP-1, MCP-3, MIP-1a,
MIP-1b, and RANTES), cytokines (i.e., IL-1, IL-3, IL-5,
IL-6), and growth factors (i.e., G-CSF, GM-CSF) to re-
cruit mature leukocytes and to stimulate the bone marrow
production of new leukocytes (34–36). It is tempting to
speculate that MPIF-1 and MPIF-2 may play an important
role promoting and then limiting these processes. Once re-
leased by activated T lymphocytes, monocytes, and tissue
macrophages, MPIF-1 and MPIF-2 could induce the mi-
gration of these same cell types to the local microenviron-
ment. More intriguing, the potential of MPIF-1 and MPIF-2
to reduce the capacity of the hematopoietic progenitor pool
to produce mature elements could limit the local accumu-
lation of proinflammatory cells. The inhibitory activity of
MPIF-1 and MPIF-2 suggests that these novel chemokines
may have the potential to protect the hematopoietic pro-
genitors from the cytotoxic effects of the antiblastic drugs
used in cancer therapy.
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Note added in proof. The cDNA sequence for MPIF-2 shown in Fig. 1 B has a typographical error at nucle-
otide 182, which is printed c rather than g. This correction results in a change of the amino acid at position
61 from a glycine (G) to an alanine (A). In addition, the MPIF-2 cDNA sequence predicts a phenylalanine at
position 73. However, data from mass spectrophotometry and sequencing studies indicates that there is a
serine at position 73 instead of a phenylalanine in the protein preparation used in this study.
References
1. Miller, M.D., and M.S. Krangel. 1992. Biology and bio-
chemistry of the chemokines: a family of chemotactic and in-
flammatory cytokines. CRC Crit. Rev. Immunol. 12:17–46.
2. Mukaida, N., A. Harada, K. Yasumoto, and K. Matsushima.
1992. Properties of proinflammatory cell type–specific leuko-
cyte chemotactic cytokines, interleukin 8 and monocyte
chemotactic and activating factor (MCAF). Microbiol. Immu-
nol. 36:773–789.
3. Kuna, P., S.R. Reddihari, D. Rucinski, J.J. Oppenheim, and
A.P. Kaplan. 1992. Monocyte chemotactic and activating
factor is a potent histamine-releasing factor for human baso-
phils. J. Exp. Med. 175:489–493.
4. Bischoff, S.C., M. Kreiger, T. Brunner, and C.A. Dahinden.
1992. Monocyte chemotactic protein 1 is a potent activator
of human basophils. J. Exp. Med. 175:1271–1275.
5. Dahinden, C.A., T. Geiser, T. Brunner, V.V. Tscharner, D.
Caput, P. Ferraa, A. Minty, and M. Baggiolini. 1994. Mono-
cyte chemotactic protein 3 is a most effective basophil- and
eosinophil-activating chemokine. J. Exp. Med. 179:751–756.
6. Taub, D.D., A.R. Lloyd, K. Conlon, J.M. Wang, J. Ortaldo,
A. Harada, K. Matsushima, D.J. Kelvin, and J.J. Oppenheim.
1993. Recombinant human IP-10 is a chemoattractant for T
lymphocytes and promotes T cell adhesion to endothelial
cells.  J. Exp. Med. 177:1809–1815.
7. Campbell, J.J., S. Qin, K.B. Bacon, C.R. Mackay, and E.C.
Butcher. 1996. Biology of chemokine and classical chemoat-
tractant receptors: differential requirements for adhesion-trig-
gering versus chemotactic responses in lymphoid cells. J. Cell
Biol. 134:255–266.
8. Del Pozo, M.A., P. Sanchez-Mateos, M. Nieto, and F.
Sanchez-Madrid. 1995. Chemokines regulate cellular polar-
ization and adhesion receptor redistribution during lympho-
cyte interaction with endothelium and extracellular matrix.
Involvement of cAMP signaling pathway. J. Cell Biol. 131:
495–508.
9. Baggiolini, M., B. Dewald, and B. Moser. 1994. Interleukin-81172 MPIF-1 and MPIF-2 Inhibition of Distinct Myeloid Progenitors
and related chemotactic cytokines-CXC and CC chemo-
kines.  Adv. Immunol. 55:97–179.
10. Oppenheim, J.J., C.O.C. Zachariae, N. Mukaida, and K.
Matsushima. 1991. Properties of the novel proinflammatory
supergene “intercrine” cytokine family. Annu. Rev. Immunol.
9:617–648.
11. Rot, A., M. Kreiger, T. Brunner, S.C. Bischoff, T.J. Schall,
and C.A. Dahinden. 1992. RANTES and macrophage in-
flammatory protein 1a induce the migration and activation of
normal human eosinophil granulocytes. J. Exp. Med. 176:
1489–1495.
12. Loetscher, P., M. Seitz, I. Clark-Lewis, M. Baggiolini, and
B. Moser. 1994. Monocyte chemotactic proteins MCP-1,
MCO-2, and MCP-3 are major attractants for human CD41
and CD81 T lymphocytes. FASEB J. 8:1055–1060.
13. Pragnell, I.B., E.G. Wright, S.A. Lorimore, J. Adam, M.
Rosendaal, J.F. Delamarter, M. Freshney, I. Eckmann, A.
Sproul, and N. Wilkie. 1988. The effect of stem cell prolifer-
ation regulators demonstrated with an in vitro assay. Blood.
72:96–99.
14. Graham, G.J., E.C. Wright, R. Hewick, S.D. Wolpe, N.M.
Wilkie, D. Donaldson, S. Lorimore, and I.B. Pragnell. 1990.
Identification and characterization of an inhibitor of hemato-
poietic stem cell proliferation. Nature (Lond.). 344:442–444.
15. Gewirtz, A.M., J. Zhang, M. Ratajczak, K.S. Park, C. Li, Z.
Yan, and M. Poncz. 1995. Chemokine regulation of human
megakaryocytopoiesis. Blood. 86:2559–2567.
16. Uguccioni, M., P. Loetscher, U. Forssmann, B. Dewald, H.
Li, S.H. Lima, Y. Li, B. Kreider, G. Garotta, M. Thelen, and
M. Baggiolini. 1996. Monocyte chemotactic protein 4 (MCP-4),
a novel structural and functional analogue of MCP-3 and eo-
taxin. J. Exp. Med. 183:2379–2384.
17. Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald, and W.J.
Rutter. 1979. Isolation of biologically active ribonucleic acid
from sources enriched in ribonuclease. Biochemistry. 18:5294–
5299.
18. Kreider, B.L., P.D. Pillips, M.D. Prystowsky, N. Shirsat, J.H.
Pierce, R. Tushinski, and G. Rovera. 1990. Induction of
granulocyte–macrophage colony-stimulating factor (CSF) re-
ceptor by granulocyte CSF increases the differentiative op-
tions of a murine hematopoietic progenitor cell. Mol. Cell
Biol. 10:4846–4851.
19. Adams, M.D., J.M. Kelly, J.D. Gocayne, M. Dubnick, M.H.
Polymeropoulos, X. Hong, C.R. Merril, A. Wu, B. Olde,
R.F. Moreno et al. 1991. Complementory DNA sequencing:
expressed sequence tags and human genome project. Science
(Wash. DC). 252:1651–1656.
20. Adams, M.D., M. Dubnick, A.R. Kerlavage, R. Moreno,
J.M. Kelly, T.R. Utterback, J.W. Nagle, C. Fields, and J.C.
Ventor. 1992. Sequence identification of 2,375 human brain
genes. Nature (Lond.). 255:632–634.
21. Hardy, M.R., and R.R. Townsend. 1994. High-pH anion-
exchange chromatography of glycoprotein-derived carbohy-
drates. Methods Enzymol. 230:208–225.
22. Boyum, A. 1976. Isolation of lymphocytes, granulocytes and
macrophages. Scand. J. Immunol. 5(Suppl.):9–15.
23. Talmadge, K.W., H. Gallati, F. Sinigaglia, A. Walz, and G.
Garotta. 1986. Identitiy between human interferon-gamma
and “macrophage-activating factor” produced by human T
lymphocytes. Eur. J. Immunol. 16:1471–1477.
24. Hansel, T.T., J.M. De Vries, T. Iff, S. Rihs, M. Wandzilak,
S. Betz, K. Blaser, and C. Walker 1991. An improved immu-
nomagnetic procedure for the isolation of highly purified hu-
man blood eosinophils. J. Immunol. Methods. 145:105–110.
25. Metcalf, D. 1984. The Hemopoietic Colony Stimulating
Factors. Elsevier Science Publishers B. V., Amsterdam. 97–
105.
26. Bradley, T.R., and G.S. Hodgson. 1979. Detection of primi-
tive macrophage progenitor cells in bone marrow. Blood. 54:
1446–1451.
27. Bertoncello, I., T.R. Bradley, G.S. Hodgson, and J.M. Dun-
lop. 1991. The resolution, enrichment and organization of
normal bone marrow high proliferative potential colony-form-
ing subsets on the basis of rhodamine 123 fluorescence. Exp.
Hematol. 19:174–182.
28. Kriegler, A.B., S.M. Verschoor, D. Ber, and I. Bertoncello.
1994. The relationship between different high proliferative
potential colony-forming cells in mouse bone marrow. Exp.
Hematol. 22:432–440.
29. Dunlop, D.J., E.G. Wright, S. Lorimore, G.J. Graham, T.
Holyoake, D.J. Kerr, S.D. Wolpe, and I.B. Pragnell. 1992.
Demonstration of stem cell inhibition and myeloprotective
effects of SCI/rhMIP-1a in vivo. Blood. 79:2221–2228.
30. Broxmeyer, H.E., B. Sherry, S. Cooper, L. Lu, R. Maze,
M.P. Beckmann, A. Cerami, and P. Ralph. 1993. Compari-
tive analysis of the human macrophage inflammatory protein
family of cytokines (chemokines) on proliferation of human
myeloid progenitor cells. J. Immunol. 150:3448–3458.
31. Quesniaux, V.F.J., G.J. Graham, I.B. Pragnell, D. Donaldson,
S.D. Wolpe, N.N. Iscove, and B. Fagg. 1993. Use of 5-fluo-
rouracil to analyze the effect of macrophage inflammatory
protein-1a on long-term reconstituting stem cells in vivo.
Blood. 81:1497–1504.
32. Bonnet, D., F.M. Lemoine, A. Najman, and M. Giugon.
1995. Comparison of the inhibitory effect of AcSDKP, TNF-a,
TGF-b, and MIP-1a on marrow-purified CD341 progeni-
tors. Exp. Hematol. 23:551–556.
33. Youn, B-S., I.-K. Jang, H.E. Broxmeyer, S. Cooper, N.A.
Jenkins, D.J. Gilbert, N.G. Copeland, T.A. Elick, M.J. Fraser,
and B.S. Kwon. 1995. A novel chemokine, macrophage inflam-
matory protein-related protein-2, inhibits colony formation
of bone marrow myeloid progenitors. J. Immunol. 155:2661–
2667.
34. Sherri, B., and A. Cerami. 1991. Small cytokine superfamily.
Curr. Opin. Immunol. 3:56–60.
35. Huffnagle, G.B., R.M. Strieter, T.J. Standiford,. R.A. Mc-
Donald, M.D. Burdick, S.L. Kunkel, and G.B. Toews. 1995.
The role of monocyte chemotactic protein-1 (MCP-1) in the
recruitment of monocytes and CD41 T cells during a pulmo-
nary Cryptococcus neoformans infection. J. Immunol. 155:4790–
4797.
36. Schrum, S., P. Probst, B. Fleischer, and P.F. Zipfel. 1996.
Synthesis of the CC-chemokines MIP-1a, MIP-1b, and
RANTES is associated with a type 1 immune response. J. Im-
munol. 157:3598–3604.